Insulin Discontinuation Tension; FDA OKs Osteopenia Belt; Limited Mounjaro Supply
(MedPage Today) -- Type 1 diabetes patients are upset over the looming discontinuation of Novo Nordisk's long-acting insulin detemir (Levemir). (USA Today)
Mid-life women with greater exposure to toxic metals like arsenic, cadmium, and mercury... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - January 30, 2024 Category: Endocrinology Source Type: news
Sanofi Is Now the Third Insulin Producer to Slash Prices
Sanofi will cut the U.S. list price of two of its insulins, making it the third major producer of the diabetes medicine to recently slash prices.
French pharmaceutical maker Sanofi will reduce the U.S. list price of Lantus, its most-prescribed insulin, by 78%, according to a statement Thursday. The company will also reduce the list price of Apidra by 70%.
“We are pleased to see others join our efforts to help patients as we now accelerate the transformation of the U.S. insulin market,” said Olivier Bogillot, the head of U.S. general medicines. “Our decision to cut the list price of our lead insulin needs ...
Source: TIME: Health - March 17, 2023 Category: Consumer Health News Authors: Ilena Peng/Bloomberg Tags: Uncategorized bloomberg wire Drugs healthscienceclimate Source Type: news
Novo Nordisk Plans Price Cuts for Several Insulins
Novo Nordisk will start slashing some U.S. insulin prices up to 75% next year, following a path set earlier this month by rival Eli Lilly.
The Danish drugmaker said Tuesday that pre-filled pens and vials of long-acting and short-acting insulins will see price reductions. They include Levemir, Novolin, NovoLog and NovoLog Mix70/30.
Novo also will drop the list price of some unbranded products to match the lower price of the branded insulins.
The price cuts go into effect Jan. 1.
Eli Lilly and Co. said March 2 that it will cut the list prices for its most commonly prescribed insulin, Humalog, and for another insulin, Humulin...
Source: TIME: Health - March 14, 2023 Category: Consumer Health News Authors: Associated Press Tags: Uncategorized Drugs healthscienceclimate wire Source Type: news
Here ’s How the Other Major Insulin Makers Are Responding After Eli Lilly’s Price Cap
Facing pressure to curb diabetes-treatment costs, Eli Lilly & Co. announced on March 1 that it is slashing insulin prices and immediately capping the out-of-pocket cost of all of its insulins at $35 a month. President Joe Biden, who made insulin costs a focus of his State of the Union speech last month, praised the move by Lilly and called on other drugmakers to also lower insulin prices.
The price cuts by the Indianapolis-based Lilly, one of the world’s top three insulin producers, are expected to provide critical relief to the millions of Americans who rely on the medicine to control their blood sugar levels. S...
Source: TIME: Health - March 2, 2023 Category: Consumer Health News Authors: Nik Popli Tags: Uncategorized Drugs News Team Source Type: news
Insulin Degludec vs Detemir; Cooking Classes for Kids; KDIGO's Drug Guide
(MedPage Today) -- Among pregnant women with type 1 diabetes, using insulin degludec was noninferior to insulin detemir for glucose control and safety. (The Lancet Diabetes & Endocrinology)
Even the lowest dose (3 mg/kg) of the investigational... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - January 10, 2023 Category: Endocrinology Source Type: news
Novo Nordisk Issues Voluntary Nationwide Recall of Levemir ®, Tresiba®, Fiasp®, Novolog® and Xultophy® Product Samples Due to Improper Storage Temperature Conditions
Novo Nordisk is voluntarily recalling 1,468 product samples listed in the table below of Levemir ®, Tresiba®, Fiasp®, Novolog® and Xultophy®, to the consumer level. These products are being recalled because they were stored at temperatures below storage requirements. This recall only impacts product (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 10, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Insulins Detemir and Glargine Safe in Diabetes Pregnancies Insulins Detemir and Glargine Safe in Diabetes Pregnancies
Use of insulin detemir in women with pre-existing diabetes who become pregnant appears safe, according to the results of the EVOLVE study.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 28, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Insulins Determir and Glargine Safe in Diabetes Pregnancies Insulins Determir and Glargine Safe in Diabetes Pregnancies
Use of insulin detemir in women with pre-existing diabetes who become pregnant appears safe, according to the results of the EVOLVE study.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 28, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Levemir (Insulin Detemir) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 25, 2019 Category: Drugs & Pharmacology Source Type: news
Insulia wins FDA nod, CE Mark clearance to titrate Tresiba, Basaglar insulin
Voluntis said today that its digital management system for people with Type II diabetes, Insulia, won FDA clearance and CE Mark approval to integrate basal insulin brands Tresiba and Basaglar. The company’s software already works with Lantus, Toujeo and Levemir.
The Insulia digital companion is composed of a patient mobile app and healthcare worker web portal. The app gives real-time basal insulin dosing recommendations and educational coaching messages based on blood glucose levels to patients with Type II diabetes.
Get the full story at our sister site, Drug Delivery Business News.
The post Insulia wins FDA nod, CE Ma...
Source: Mass Device - November 16, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Voluntis Source Type: news
Voluntis wins regulatory nod to integrate Toujeo insulin with Insulia mobile app
Voluntis said today its digital management system for people with Type II diabetes, Insulia, won FDA clearance and CE Mark approval to integrate Sanofi‘s (NYSE:SNY) Toujeo insulin glargine. The company’s software already works with Lantus and Levemir.
The Insulia digital companion is composed of a patient mobile app and healthcare worker web portal. The app gives real-time basal insulin dosing recommendations and educational coaching messages based on blood glucose levels to patients with Type II diabetes. The web portal enables healthcare practitioners to develop personalized treatment plans and track their patient ...
Source: Mass Device - July 18, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Health Information Technology Pharmaceuticals Regulatory/Compliance Software / IT Wall Street Beat Sanofi-Aventis Voluntis Source Type: news
Novo Nordisk eyes drug development program
Novo Nordisk (NYSE:NVO) is betting on a risky drug development strategy, like re-engineering insulin to act selectively on the liver or only when blood sugar is high, according to the Wall Street Journal.
Nordisk has focused on developing fast-acting insulin to inject at mealtime and another variety for a steady supply of insulin throughout the day. Its most recent insulin product, Tresiba, provides a near-stable level of insulin in the blood for 40 hours. Tresiba sells for $443.85 for 15 milliliters, 10% higher than its predecessor Levemir.
“The next steps will take innovation to an even higher level,” resea...
Source: Mass Device - October 3, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Business/Financial News Diabetes Research & Development Novo Nordisk Source Type: news
Insulin Nasal Spray as Treatment for Alzheimer's Dementia
The study's subjects were 60 adults diagnosed with amnesic mild cognitive impairment (MCI) or mild to moderate Alzheimer's dementia (AD). Those who received nasally-administered 40 international unit (IU) doses of insulin detemir, a manufactured form of the hormone, for 21 days showed significant improvement in their short-term ability to retain and process verbal and visual information compared with those who received 20 IU does or a placebo. (Source: Disabled World)
Source: Disabled World - January 11, 2015 Category: Disability Tags: Aging Associated Diseases Source Type: news
Nasal spray with insulin equivalent shows promise as treatment for adults with mild cognitive impairment, Alzheimer’s dementia
A human-made form of insulin delivered by nasal spray may improve working memory and other mental capabilities in adults with mild cognitive impairment and Alzheimer's disease dementia, according to a pilot study. The researchers also sought to determine if the insulin detemir doses would cause any negative side effects, and found only minor adverse reactions among the subjects. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 8, 2015 Category: Science Source Type: news
Insulin Analogues Have Edge in Curbing Severe HypoglycemiaInsulin Analogues Have Edge in Curbing Severe Hypoglycemia
Compared with human insulin, insulin detemir and aspart significantly reduce recurrent hypoglycemia in many type 1 diabetics prone to such events, according to Danish researchers. Nevertheless, individual responses vary. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 28, 2014 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
